{
    "clinical_study": {
        "@rank": "87376", 
        "arm_group": [
            {
                "arm_group_label": "tadalafil, dutasteride", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "dutasteride, tadalafil", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This is an open-label, two-arm, one-sequence, cross-over study to evaluate the safety and\n      pharmacokinetic interaction after oral concomitant administration of tadalafil and\n      dutasteride in healthy male volunteers."
        }, 
        "brief_title": "Safety and Pharmacokinetic Interaction Study of Tadalafil and Dutasteride", 
        "condition": "Benign Prostate Hyperplasia", 
        "condition_browse": {
            "mesh_term": [
                "Prostatic Hyperplasia", 
                "Hyperplasia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  1. Age 20 to 29 years 2. Weight 60 kg or more, within 20% of Ideal body weight 3. No\n             congenital or chronic diseases, no disease symptoms or findings 4. Eligible according\n             to the laboratory results of hematology, blood chemistry and urinalysis 5.\n             Voluntarily signed the informed consent form\n\n        Exclusion Criteria:\n\n          -  1. Clinically significant disorders of hepatobiliary system, kidney, neurology,\n             respiratory, hemato-oncology, endocrine, dermatology, urology, ophthalmology,\n             psychiatry, musculo-skeletal system, immunology, otorhinolaryngology, and\n             cardiovascular system 2. Gastrointestinal diseases or surgery which may affect\n             absorption of the investigational products 3. hypersensitivity to tadalafil or\n             phosphodiesterase type 5 inhibitor, and dutasteride or 5-\u03b1 reductase inhibitor 4.\n             Lactose intolerance 5. SBP \u2265 140 mmHg or < 90 mmHg or DBP \u2265 95 mmHg or < 60 mmHg 6.\n             Serum creatinine > ULN 7. History or positive result of drug abuse 8. Drugs which\n             induce or inhibit drug metabolism including barbiturates within 1 month 9. Prescribed\n             drugs or herbal medicines within 2 weeks, or over-the counter drugs or vitamins\n             within 1 week 10. CYP3A4 inhibitors or CYP3A4 inducers within 2 weeks 11. Food\n             including grapefruit from Week -1 to final dose 12. Participated and administered the\n             investigational products in other clinical trial within 2 months 13. Donated whole\n             blood within 2 months or apheresis within 1 month, or transfusion within 1 month 14.\n             Plans to donate blood for at least 6 months after final dose of dutasteride 15.\n             Scheduled dental treatment and elective surgery from informed consent to post-study\n             visit 16. Excessive alcohol consumption (> 21 units/week, 1 unit = 10 g of pure\n             alcohol) 17. Smoked more than 10 cigarettes a day for past 3 months 18. Not eligible\n             due to other reasons including laboratory results"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "29 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01942551", 
            "org_study_id": "DK-DT-001"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "tadalafil, dutasteride", 
                    "dutasteride, tadalafil"
                ], 
                "intervention_name": "Tadalafil", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "tadalafil, dutasteride", 
                    "dutasteride, tadalafil"
                ], 
                "intervention_name": "Dutasteride", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dutasteride", 
                "Tadalafil"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 15, 2013", 
        "location": {
            "contact": {
                "email": "zeusy@cnuh.co.kr", 
                "last_name": "JaeWoo Kim", 
                "phone": "+82-42-280-8618"
            }, 
            "facility": {
                "address": {
                    "city": "Daejeon", 
                    "country": "Korea, Republic of", 
                    "zip": "301-721"
                }, 
                "name": "Chungnam National University Hospital"
            }, 
            "investigator": {
                "last_name": "JaeWoo Kim, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Area Under Curve (AUC) of tadalafil", 
                "safety_issue": "No", 
                "time_frame": "0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 16, 24 h"
            }, 
            {
                "measure": "Cmax of tadalafil", 
                "safety_issue": "No", 
                "time_frame": "0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 16, 24 h"
            }, 
            {
                "measure": "Area Under Curve (AUC) of dutasteride", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 32, 48, 72, 96, 144, 192, 240, 288, 336 h"
            }, 
            {
                "measure": "Cmax of dutasteride", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 32, 48, 72, 96, 144, 192, 240, 288, 336 h"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01942551"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Dongkook Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dongkook Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}